Cannabis Pharmaceuticals Market Research Report by Brand, Product Type, Distribution Channel, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

The Global Cannabis Pharmaceuticals Market size was estimated at USD 1,031.56 million in 2021 and expected to reach USD 1,222.09 million in 2022, and is projected to grow at a CAGR 18.64% to reach USD 2,877.64 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Cannabis Pharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Brand, the market was studied across Epidiolex and Sativex.

Based on Product Type, the market was studied across Ointments & Creams and Solids and Dissolvable Powder & Oil.

Based on Distribution Channel, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on Application, the market was studied across Arthritis, Cancer, Epilepsy, and Migraine.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cannabis Pharmaceuticals market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cannabis Pharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cannabis Pharmaceuticals Market, including AbbVie Inc., Amyris, Inc., Aphria, Inc., Aurora Cannabis, Inc., Botanix Pharmaceuticals, Breath of Life Pharma, Ltd., Cannabis Science, Inc., Canopy Growth Corporation, Cara Therapeutics, CB Therapeutics Inc., Corbus Pharmaceuticals Holdings, Inc., Cronos Group Inc., GW Pharmaceuticals, PLC, Insys Therapeutics, Inc., Medical Marijuana Inc., Medicure Pharmaceuticals, MedReleaf Corp., MGC Pharmaceuticals Limited, Pascal Biosciences Inc., PharmaCyte Biotech, Inc., Serina Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Tilray, Inc., Valeant Pharmaceuticals, and Zynerba Pharmaceuticals, Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Cannabis Pharmaceuticals Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cannabis Pharmaceuticals Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cannabis Pharmaceuticals Market?
4. What is the competitive strategic window for opportunities in the Global Cannabis Pharmaceuticals Market?
5. What are the technology trends and regulatory frameworks in the Global Cannabis Pharmaceuticals Market?
6. What is the market share of the leading vendors in the Global Cannabis Pharmaceuticals Market?
7. What modes and strategic moves are considered suitable for entering the Global Cannabis Pharmaceuticals Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in the legalization of medicinal cannabis in economies
5.1.1.2. Growing awareness about the medical benefits of cannabidiol and its remedial properties
5.1.1.3. Growing usage of cannabis-based pharmaceuticals for various indications such as inflammation, chronic pain, sleep disorders, and others
5.1.2. Restraints
5.1.2.1. High price associated with the medical cannabis
5.1.3. Opportunities
5.1.3.1. Rise in investments by pharma companies in CBD and developments for cannabinoid regulation
5.1.3.2. Innovation and launching new products
5.1.4. Challenges
5.1.4.1. Availability of various alternatives in the market
5.2. Cumulative Impact of COVID-19

6. Cannabis Pharmaceuticals Market, by Brand
6.1. Introduction
6.2. Epidiolex
6.3. Sativex

7. Cannabis Pharmaceuticals Market, by Product Type
7.1. Introduction
7.2. Ointments & Creams
7.3. Solids and Dissolvable Powder & Oil

8. Cannabis Pharmaceuticals Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies

9. Cannabis Pharmaceuticals Market, by Application
9.1. Introduction
9.2. Arthritis
9.3. Cancer
9.4. Epilepsy
9.5. Migraine

10. Americas Cannabis Pharmaceuticals Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cannabis Pharmaceuticals Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cannabis Pharmaceuticals Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. AbbVie Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Amyris, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Aphria, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Aurora Cannabis, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Botanix Pharmaceuticals
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Breath of Life Pharma, Ltd.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Cannabis Science, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Canopy Growth Corporation
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Cara Therapeutics
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. CB Therapeutics Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Corbus Pharmaceuticals Holdings, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Cronos Group Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. GW Pharmaceuticals, PLC
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Insys Therapeutics, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Medical Marijuana Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Medicure Pharmaceuticals
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. MedReleaf Corp.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. MGC Pharmaceuticals Limited
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Pascal Biosciences Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. PharmaCyte Biotech, Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Serina Therapeutics, Inc.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Teva Pharmaceutical Industries Ltd.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Tilray, Inc.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Valeant Pharmaceuticals
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Zynerba Pharmaceuticals, Inc.
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing